An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study

BACKGROUND: Patients with melanoma brain metastasis (MBM) still carry a dismal prognosis. Preclinical data originated in xenograft models showed that buparlisib therapy was highly effective in therapy-naïve MBM. PATIENTS AND METHODS: In this open-label, phase II trial, we investigate the safety and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurooncol Adv
Egile Nagusiak: Amaral, Teresa, Niessner, Heike, Sinnberg, Tobias, Thomas, Ioannis, Meiwes, Andreas, Garbe, Claus, Garzarolli, Marlene, Rauschenberg, Ricarda, Eigentler, Thomas, Meier, Friedegund
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Clinical Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7712798/
https://ncbi.nlm.nih.gov/pubmed/33305271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa140
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak